SQZ Biotech Strengthens Tech Capabilities

SQZ Biotechnologies, a Massachusetts-based clinical-stage biotechnology company, is focused on utilizing the complete potential of cell therapies targeting multiple therapeutic areas with a motto of “Empowering Cells to Change Lives”.

The company announced on Thursday, July 1, the appointment of new expertise Bernard Coulie, M.D., Ph.D., and Patrick Vinc, M.D., welcoming them to the company’s board of directors table, incorporating insights of global commercial and clinical development expertise.

Bernard Coulie reflects over 20 years of experience focused on drug development along with company development and formation and growth. As of present, he is the President and CEO of Pliant Therapeutics, which was followed after he cofounded the Belgium-based Acto-GeniX, and was the CEO from 2006 until it underwent acquisition in 2015. Dr. Coulie also held robust responsibilities associated with drug discovery and clinical research during his employment at Johnson & Johnson Europe. Patrick Vinc, the second appointment made by SQZ has more than 30 years of experience serving as a senior executive in the life science industry. Dr. Vinc has served as an Executive Vice president at Cubist in the past. He was the head of the Global Biopharmaceuticals facility situated in Sandoz of Novartis Group.

Patrick has previously served as the Vice President managing International Business for Biogen Inc.The company expressed its enthusiasm with the newly appointed board of members suggesting the execution of clinical trials in line with expanding the pipeline addressing multiple disease areas with SQZ novel cell therapies, stated Armon Sharei, Ph.D., Chief Executive Officer of SQZ Biotechnologies.